Blog Immunotherapy 360: Bispecific T-cell engaging antibodies (BiTEs)

Bispecific T-cell engaging antibodies (BiTEs)

The Immunotherapy 360 blog space features articles that encompass prominent issues related to immunotherapy. These are written with the assistance of the staff at AIM at Melanoma, AIM with Immunotherapy and health care practitioners.

If you have an idea for a future article, please reach out to us on our contact page!

Featured image for “Cytokine Release Syndrome”

Cytokine Release Syndrome

October 22, 2025
Introduction The approval and availability of cancer immunotherapies have significantly advanced treatment outcomes for patients with melanoma and with other…

Recent Posts

Featured image for “COVID-19 mRNA Vaccines and Improved Response to Immunotherapy”
Nov. 02, 2025

COVID-19 mRNA Vaccines and Improved Response to Immunotherapy

Featured image for “Cytokine Release Syndrome”
Oct. 22, 2025

Cytokine Release Syndrome

Featured image for “Regeneron Announces Approval of Cemiplimab-rwlc for Adjuvant Treatment of Cutaneous Squamous-Cell Carcinoma with a High Risk of Recurrence After Surgery and Radiation  ”
Oct. 09, 2025

Regeneron Announces Approval of Cemiplimab-rwlc for Adjuvant Treatment of Cutaneous Squamous-Cell Carcinoma with a High Risk of Recurrence After Surgery and Radiation  

Post Categories